In Competition to Discover Tomorrow’s Proteins, XPRIZE Unveils Semifinalist Teams in XPRIZE Feed the Next Billion
13.7.2021 15:00:00 EEST | Business Wire | Press release
Today, XPRIZE is pleased to announce the 28 semifinalist teams moving forward in XPRIZE Feed the Next Billion. The $15 million competition, launched in December 2020, is aimed at reinventing how humanity will feed future generations by incentivizing the production of structured chicken breast or fish fillet alternatives that replicate or outperform conventional chicken and fish in access, environmental sustainability, animal welfare, nutrition and health, as well as taste and texture.
Selected by the competition’s panel of judges, the 28 semi-finalist teams were chosen based on their technical submissions and represent 14 countries.
Over the next year, semifinalists will work closely with the competition’s ecosystem and sponsors, which include ASPIRE and The Tony Robbins Foundation, as they begin to develop the first iteration of their products. From the Semifinalist teams, up to 10 Finalist teams will be chosen based on the merit of their technical solution prototypes towards the end of 2022 and will split a milestone award of $2.5 million. Finalist teams will enter one last round of solution development before final judging which will award one grand prize team a prize of $7 million, second & third place prizes of $2 and $1 million respectively, and a bonus prize of $2 million. The winning teams will need to create at least twenty-five cuts of structured chicken breast or fish fillet analogs of 115 gram or four ounce that replicate the sensory properties, versatility, and nutritional profile of conventional chicken or fish.
XPRIZE is pleased to share that the following teams have been selected to move forward in the competition:
- Air Protein, United States
- Another Fish, Canada
- Atlast Food Co, United States
- BlueNalu, United States
- Boston Meats, United States
- Brew51, India
- CELL AG TECH, Canada
- CellX, China
- DiverseFarm-Structured Meat, Japan
- ENOUGH - NO LIMITS, United Kingdom
- GOOD Meat, United States
- IntegriCulture, Japan
- Kernel Mycofoods, Argentina
- Kuleana, United States
- MeatOurFuture, South Africa
- Meati Foods, United States
- MyoWorks, India
- Novel Farms, United States
- ProFillet, Canada
- Revo Foods, Austria
- SeaSpire, New Zealand
- TFTAK, Estonia
- The Better Meat Co, United States
- The PlantEat, South Korea
- Umami Meats, Singapore
- Umiami, France
- Whiteboard Foods, Canada
- Wildtype, United States
“Over the past several years, as our global population continues to grow and the demand for meat products increases, it has become clear that our current global food chain cannot keep up,” said Caroline Kolta, XPRIZE Feed the Next Billion Program Lead. “We know we need more nutritious, environmentally-friendly and sustainable alternatives to conventional animal-based products, and that wide scale adoption will require additional innovation continuously being brought to market. I am thrilled about the international cohort of Semifinalists selected to embark on this journey of innovation and exploration to shape a future of food, starting with chicken and fish.”
The XPRIZE Feed the Next Billion judging panel consists of a diverse, international group of tech industry experts working at the highest levels of academia and research. The 8 judges include:
- Amy C. Rowat, Associate Professor of Integrative Biology and Physiology at the University of California, Los Angeles
- Brian Jacobson, Assistant Director of Pilot Plant Operations University of Illinois, Integrated Bioprocessing Research Laboratory (IBRL)
- Dan Blaustein-Rejto, Director of Food & Agriculture at The Breakthrough Institute
- Kantha Shelke, Ph.D., Founder and Principal at Corvus Blue LLC
- Dr. Keith Cox, Co-founder and Chief Scientific Officer of Seafood Analytics, Assistant Professor of Marine Fisheries at The University of Alaska Southeast (UAS)
- Dr. Laura Domigan, Biomaterials Scientist, University of Auckland, New Zealand
- Dr. Marcos Sanchez-Plata, Associate Professor, Global Food Security - Animal and Food Sciences at Texas Tech University
- Olivia Ogilvie, Postdoctoral Fellowship in Cellular Agriculture with a Specific Focus on Cultured Meat - The University of Auckland
XPRIZE Feed the Next Billion originated from the Future of Food Impact Roadmap, an in-depth analysis by XPRIZE of global food system challenges, which found alternative proteins at-scale to be a critical impact area requiring significant technological advances, decreased price points, and notable shifts in consumers’ preferences. The competition was then launched with the support of partners including ASPIRE, a part of Abu Dhabi’s Advanced Technology Research Council (ATRC), the technology programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC) which shapes research and development for transformative technology outcomes and defines Abu Dhabi’s R&D strategy, The Tony Robbins Foundation, The Good Food Institute, Foundation for Food and Agriculture, District 3, New Harvest, and Proveg International. Through the development of chicken and fish alternatives, teams competing in the prize will work to ensure that, as the world grows in wealth, the availability of sustainable food can meet the coming demand for food products that allow the next billion to live active and healthy lives.
To learn more about XPRIZE Feed the Next Billion, visit xprize.org/feed.
ABOUT XPRIZE
XPRIZE, a 501(c)(3) nonprofit, is the global leader in designing and implementing innovative competition models to solve the world’s grandest challenges. Active competitions include the $100 Million XPRIZE Carbon Removal with Elon Musk, $20 Million NRG COSIA Carbon XPRIZE, $15 Million XPRIZE Feed the Next Billion, $10 Million Rainforest XPRIZE, $10 Million ANA Avatar XPRIZE, $5 Million IBM Watson AI XPRIZE, $5 Million XPRIZE Rapid Reskilling and $1M Digital Learning Challenge. For more information, visit xprize.org.
About ASPIRE
ASPIRE drives the creation of future transformative technologies as the programme management pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC). ATRC is responsible for defining Abu Dhabi’s research and development strategy, consolidating funds for efficient investment and driving policy and regulation. ASPIRE works in consultation with cross-sector industry stakeholders, universities and research institutes to frame problem statements. It also launches grand challenges and international competitions to solve some of the world’s most pressing issues. ASPIRE brings together exceptional people, ideas, resources and technologies to solve complex challenges. For more information, please visit www.aspireuae.ae.
Connect with us on social media:
ABOUT THE TONY ROBBINS FOUNDATION
Founded in 1991, The Tony Robbins Foundation is a nonprofit organization created to empower individuals and organizations to make a significant difference in the quality of life of people often forgotten. Through global programs and initiatives, The Tony Robbins Foundation is dedicated to creating positive changes in the lives of youth, seniors, the hungry, homeless and the imprisoned population. The Foundation helps provide millions of meals globally each year, has awarded over 2,000 grants and other resources to health and human services organizations, implemented curriculum in 1,700 plus correctional facilities and gathered thousands of young leaders from around the world with its teen programs. For more information, visit www.thetonyrobbinsfoundation.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210713005621/en/
Contact information
Caden Kinard, 949-280-0182
caden.kinard@xprize.org
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
